Acadia (ACAD) is successfully navigating the dangerous trek from FDA approval to commercial success. It still has a way to go. At this stage it has established a track record of success in marketing its Nuplazid (pimavanserin) therapy for its approved indication.
Acadia's existing FDA approval gives investors confidence that it will have the wherewithal to run out its remaining clinical trials. The real fizz in Acadia's soda is its potential to corral a second FDA approval. This article will explore Acadia's current financial position and its near-to-mid term prospects.